Capecitabine: effective oral fluoropyrimidine chemotherapy
- 15 June 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 6 (7), 1231-1239
- https://doi.org/10.1517/14656566.6.7.1231
Abstract
Fluoropyrimidine chemotherapy, principally with 5-fluorouracil (5-FU), has been a standard of care for a range of solid tumours for many years. Capecitabine, a precursor of 5-FU, is an oral fluoropyrimidine cytotoxic agent developed with the aim of providing a more effective, less toxic alternative to 5-FU, with the added advantage of oral administration. In clinical trials, capecitabine has proven to be an effective substitute for 5-FU in colorectal and breast cancer, and has become an accepted standard treatment in these tumours, both as a single agent and as a component of combination chemotherapy. It is also effective in a number of other solid tumours and as a radiosensitising agent. Capecitabine has significantly less serious toxicity than 5-FU when used alone or in combination with other cytotoxic agents. It has been shown to be resource saving in comparison with accepted standard comparator regimens in breast and colorectal cancer. Ongoing and future clinical trials will continue to examine, and are likely to expand, the role of capecitabine in the treatment of breast and colorectal cancer, as well as a number of other malignancies, both in the advanced palliative and adjuvant curative settings. This will involve the use of capecitabine as a single agent and increasingly in combination with other new anticancer agents.Keywords
This publication has 44 references indexed in Scilit:
- Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II StudyJournal of Clinical Oncology, 2004
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancerGynecologic Oncology, 2004
- Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancerActa Oncologica, 2004
- Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabineCancer, 2004
- Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal CancerJournal of Clinical Oncology, 2003
- EditorialClinical Oncology, 2003
- Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic CancerJournal of Clinical Oncology, 2002
- Clinical Pharmacokinetics of CapecitabineClinical Pharmacokinetics, 2001
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998